Mammary Cell News Volume 4.43 | Nov 1 2012

LABORATORY RESEARCH

A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology Directed Repair Activity
Scientists classified six new BRCA2 variants of uncertain significance as pathogenic or non-pathogenic by analysis of genetic information from families carrying 65 individual BRCA2 DNA binding domain missense mutations using a multifactorial likelihood model of cancer causality. [Cancer Res] Abstract

HER2-Associated Radiation Resistance of Breast Cancer Stem Cells Isolated from HER2-Negative Breast Cancer Cells
Compared to HER2-negative breast cancer stem cells, HER2+/CD44+/CD24-/low cells showed elevated aldehyde dehydrogenase activity and aggressiveness tested by matrigel invasion, tumor sphere formation and in vivo tumorigenesis. [Clin Cancer Res] Abstract

Quantitative Proteomics with siRNA Screening Identifies Novel Mechanisms of Trastuzumab Resistance in HER2 Amplified Breast Cancers
Many of the known mechanisms of trastuzumab resistance cause changes in protein phosphorylation patterns and therefore quantitative proteomics was used to examine phosphotyrosine signaling networks in trastuzumab resistance cells. [Mol Cell Proteomics] Abstract

A Tumor Suppressor Role for srGAP3 in Mammary Epithelial Cells
Scientists described a potential role for srGAP3 as a tumor suppressor in mammary epithelial cells. They showed that RNAi-mediated depletion of srGAP3 promotes Rac dependent, anchorage-independent growth of partially transformed human mammary epithelial cells. [Oncogene] Abstract

H2A.Z-Dependent Crosstalk between Enhancer and Promoter Regulates Cyclin D1 Expression
Investigators showed that in triple negative breast cancer cells, H2A.Z bound to the promoter of the constitutively, weakly expressed cyclin D1 oncogene, a key regulator of cellular proliferation. [Oncogene] Abstract

p130Cas/Cyclooxygenase-2 Axis in the Control of Mesenchymal Plasticity of Breast Cancer Cells
Researchers used silencing strategies and rescue experiments to evaluate phenotypic and biochemical changes from mesenchymal to epithelial traits in breast tumor cell lines. [Breast Cancer Res]
Abstract | Full Article

ARTEMIN Stimulates Radio- and Chemo-Resistance by Promoting TWIST1-BCL-2 Dependent Cancer Stem Cell-Like Behavior in Mammary Carcinoma Cells
Investigators examined a potential role of ARTEMIN (ARTN) in the promotion of the cancer stem cell like phenotype in mammary carcinoma cells. Acquired resistance of estrogen receptor negative mammary carcinoma cells to either ionizing radiation or paclitaxel was accompanied by increased ARTN expression. [J Biol Chem] Abstract

Significance of Heterogeneous Twist2 Expression in Human Breast Cancers
Investigators examined Twist2 expression pattern in human breast carcinomas by western blot and tissue microarray, and analyzed Twist2 cellular localization by confocal microscopy, cell fractionation and other approaches. [PLoS One] Full Article

NLK Is a Novel Therapeutic Target for PTEN Deficient Tumor Cells
By combining the use of isogenic models of phosphatase and tensin homolog (PTEN) deficiency with high-throughput RNA interference screening, researchers have identified Nemo-Like Kinase (NLK) inhibition as being synthetically lethal with PTEN deficiency. [PLoS One] Full Article
 
CLINICAL RESEARCH

Incidence and Predictors of Ovarian Function Recovery in Breast Cancer (BC) Patients with Chemotherapy-Induced Amenorrhea Who Switched from Tamoxifen to Exemestane
Investigators carried out a prospective study to assess ovarian function in estrogen receptor-positive BC patients on tamoxifen who had at least two years of chemotherapy-induced amenorrhea and postmenopausal E2 levels. [Ann Oncol] Abstract

Correlation between Response to Neoadjuvant Chemotherapy and Survival in Locally Advanced Breast Cancer Patients
Researchers reported survival and tumor response according to the measurement of residual breast cancer burden, the Miller and Payne classification and the Response Evaluation Criteria in Solid Tumors criteria, in 151 locally advanced breast cancer patients. [Ann Oncol] Abstract

NIH-CRM Awards Cellular Dynamics up to $7 Million to Produce Human Induced Pluripotent Stem Cells and Differentiated Tissue Cells
The National Institutes of Health Center for Regenerative Medicine (NIH-CRM) has awarded Cellular Dynamics International, Inc. a contract to provide human induced pluripotent stem cell lines and terminally differentiated tissue cells from normal or specified patient populations. The contract is worth up to $7.0 million for the three year life of the agreement. [Cellular Dynamics International, Inc.] Press Release

NCIS/NUH Stem Cell Transplant Program Receives International Accreditation
The hematopoietic stem cell transplantation program at the National University Cancer Institute (NCIS) and National University Hospital (NUH) has received internationally-recognized accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT) at the University of Nebraska Medical Center. The program at NCIS and NUH is the first and only one in Asia to be recognized so far. [National University Hospital]
Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 1st Symposium of the Cancer Research Center of Lyon
Februrary 13-15, 2013
Lyon, France

Visit our events page to see a complete list of events in the mammary cell community.

Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Product Quality Scientist (STEMCELL Technologies, Inc.)

Product Manager – Hematopoietic (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Associate Attending Breast Pathologist (Memorial Sloan-Kettering Cancer Center)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

Postdoctoral Fellow – Breast Cancer Research (Albert Einstein College Medicine)

Higher Scientific Officer – Histopathology/Breast Pathology (Institute of Cancer Research)

Laboratory Heads – Developmental Biology and Stem Cell Biology (RIKEN Center for Developmental Biology)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.